Zydus Cadila receives USFDA approval for Pimavanserin Capsules

5 Jan 2022 , 01:34 AM

Zydus Cadilas US subsidiary Zydus Pharmaceuticals USA Inc has received tentative approval from the USFDA to market Pimavanserin Capsules in the strength of 34 mg USRLD Nuplazid Capsules Pimavanserin is an atypical antipsychotic and is indicated for the treatment of hallucinations and delusions associated with Parkinsons disease psychosis The drug will be manufactured at the groups formulation manufacturing facility at SEZ Ahmedabad The group now has 325 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04